» Articles » PMID: 35883620

Effects of Toxic AGEs (TAGE) on Human Health

Overview
Journal Cells
Publisher MDPI
Date 2022 Jul 27
PMID 35883620
Authors
Affiliations
Soon will be listed here.
Abstract

The habitual and excessive consumption of sugar (i.e., sucrose and high-fructose corn syrup, HFCS) is associated with the onset and progression of lifestyle-related diseases (LSRD). Advanced glycation end-products (AGEs) have recently been the focus of research on the factors contributing to LSRD. Approaches that inhibit the effects of AGEs may be used to prevent and/or treat LSRD; however, since the structures of AGEs vary depending on the type of reducing sugars or carbonyl compounds to which they respond, difficulties are associated with verifying that AGEs are an etiological factor. Cytotoxic AGEs derived from glyceraldehyde, a triose intermediate in the metabolism of glucose and fructose, have been implicated in LSRD and are called toxic AGEs (TAGE). A dietary imbalance (the habitual and excessive intake of sucrose, HFCS, or dietary AGEs) promotes the generation/accumulation of TAGE in vivo. Elevated circulating levels of TAGE have been detected in non-diabetics and diabetics, indicating a strong relationship between the generation/accumulation of TAGE in vivo and the onset and progression of LSRD. We herein outline current findings on "TAGE as a new target" for human health.

Citing Articles

Fructose-mediated AGE-RAGE axis: approaches for mild modulation.

Semchyshyn H Front Nutr. 2024; 11:1500375.

PMID: 39698244 PMC: 11652219. DOI: 10.3389/fnut.2024.1500375.


Toxic AGEs (TAGE) Cause Lifestyle-Related Diseases.

Takeuchi M Antioxidants (Basel). 2024; 13(11).

PMID: 39594514 PMC: 11591050. DOI: 10.3390/antiox13111372.


Slot Blot- and Electrospray Ionization-Mass Spectrometry/Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry-Based Novel Analysis Methods for the Identification and Quantification of Advanced Glycation End-Products in the Urine.

Takata T, Inoue S, Kunii K, Masauji T, Miyazawa K Int J Mol Sci. 2024; 25(17).

PMID: 39273579 PMC: 11395049. DOI: 10.3390/ijms25179632.


Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and Immune-Related Diseases.

Shen C, Lu C, Cheng C, Li K, Kuo Y, Wu C Biomedicines. 2024; 12(8).

PMID: 39200164 PMC: 11352041. DOI: 10.3390/biomedicines12081699.


Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways.

de Lima E, Moretti Jr R, Pomini K, Fornari Laurindo L, Sloan K, Sloan L Biology (Basel). 2024; 13(7).

PMID: 39056712 PMC: 11273409. DOI: 10.3390/biology13070519.


References
1.
Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T . Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res. 2007; 39(11):845-8. DOI: 10.1055/s-2007-991176. View

2.
Sakata K, Hayakawa M, Yano Y, Tamaki N, Yokota N, Eto T . Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev. 2013; 29(8):624-30. DOI: 10.1002/dmrr.2437. View

3.
Remigante A, Spinelli S, Trichilo V, Loddo S, Sarikas A, Pusch M . d-Galactose induced early aging in human erythrocytes: Role of band 3 protein. J Cell Physiol. 2021; 237(2):1586-1596. PMC: 9299479. DOI: 10.1002/jcp.30632. View

4.
Yamagishi S, Adachi H, Matsui T, Nakamura K, Takeuchi M, Enomoto M . Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects. Clin Cardiol. 2009; 32(9):E12-5. PMC: 6653735. DOI: 10.1002/clc.20532. View

5.
Takino J, Sato T, Kanetaka T, Okihara K, Nagamine K, Takeuchi M . RasGRP2 inhibits glyceraldehyde-derived toxic advanced glycation end-products from inducing permeability in vascular endothelial cells. Sci Rep. 2021; 11(1):2959. PMC: 7859393. DOI: 10.1038/s41598-021-82619-0. View